Micronising APIs under containment

Published: 16-Jun-2015

The poor solubility and bioavailability of today’s APIs can be addressed via micronisation. Swiss group Dec looks at the latest technology for reducing the particle size of potent APIs

You need to be a subscriber to read this article.
Click here to find out more.

One of the preferred drug applications is oral drug administration. As per the Biopharmaceutics Classification System (an FDA system that differentiates drugs on the basis of their solubility and permeability)1, the number of poorly soluble drugs has increased in recent years and only a few of the new drug molecules are characterised with having both solubility and permeability. To achieve the desired pharmacological effect, however, bioavailability and hence the solubility of the drug is of prime importance. According to the Noyes-Whitney equation* the dissolution rate can be significantly increased by particle size reduction. Reduced particle size is also a crucial factor for the success of inhalation therapies.

Only a few techniques can break down particles to within the desired size range, one of which is controlled micronisation. Spiral jet mill micronisation of solid materials in either standard, contained or aseptic format is an area of expertise of Dec, a producer of powder handling, isolation and containment systems.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like